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The mitochondrion is a subcellular organelle with major functions related to energy 
production and control of apoptosis. The presence of mitochondria as a subcellular organelle 
has been known for more than one and a half century. However, only the last decades’ 
research has discovered their role in ageing and disease pathology, which have led to 
increasing interest in mitochondria as target for drug delivery. For a long time the 
mitochondria were thought to be static organelles, however, it was then discovered that they 
continuously fused together forming tubular networks followed by fission back into single 
organelles. 
The aim of the work was to evaluate whether liposomes could be recognized as artificial 
mitochondria and thereby be included in the fusion-fission cycle. 
Liposomes were prepared with different lipid compositions mimicking the composition of the 
outer mitochondrial membrane. A lipophilic fluorescent dye was incorporated in liposomes to 
evaluate their ability to fuse with isolated mitochondria.  
Based on the fusion experiments, it was confirmed that the level of fusion was altered in 
respect to the different lipid compositions. 
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1 General introduction 
Mitochondria are a subcellular organelles thought to rise from the endosymbiosis theory 
(Nunnari and Suomalainen, 2012). They have a distinct structure consisting of two 
membranes which is important in one of their major functions; producing the energy, in form 
of adenosine triphosphate (ATP), the cell need to carry on its function (Kowald and 
Kirkwood, 2011a). They are also important regarding their role in controlling apoptosis and 
mitochondrial dysfunctions shows to be the cause of an increasing number of human 
disorders (Nunnari and Suomalainen, 2012). 
It was earlier thought that mitochondria were static organelles, but they were later shown to 
be quiet dynamic with a constant on-going cycle of alternating fusion and fission (Kowald 
and Kirkwood, 2011a). Evidence shows that alternating fusion and fission is necessary as a 
quality control in order to repair or destroy damaged organelles (Otera and Mihara, 2012). 
The accurate delivery of proteins and lipids due to different needs regarding intracellular 
location (Otera and Mihara, 2012) and correct distribution in cell division (Zungu et al., 2011) 
is also managed by this cycle. 
Liposomes are a novel form of drug delivery systems, although they have been known for 
several decades (Brandl, 2001). Different lipids are distributed differently in biological 











2.1.1 Structure and characteristics  
The mitochondrion is an approximately 2 μm long eukaryotic subcellular organelle which is 
thought to originate from the endosymbiosis theory. This theory states that an oxygen 
consuming bacterium was engulfed by a eukaryotic ancestor cell (Nunnari and Suomalainen, 
2012). Since both had benefits from the others function they stayed together in a symbiotic 
relationship (Jianping, 2010).  
There are two main factors, from a structural point of view, which differs the mitochondria 
from the other organelles – the double membrane, as illustrated in Figure 1, and the presence 
of mitochondrial DNA (mtDNA). 
 
Figure 1 Structure (left) (MolecularExpressions™, 2004) and micrograph (right) 
(Kimball'sBiologyPages, 2012) of mitochondria 
 
The double membrane consists of the outer mitochondrial membrane (OMM) and the inner 
mitochondrial membrane (IMM), both being phospholipid bilayers but with different 
composition, divided by an intermembrane space (IMS). The OMM consists of porins which 
allows ions and small molecules from cytosol to freely move into IMS. The IMS contain 
important ions, molecules and proteins for the mitochondrion to maintain normal functions. 
This includes protons responsible for the membrane potential and key participants in ATP 
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production and cytochrome c (cyt c) which serves as an inducing agent in apoptosis.  The 
IMM works as a barrier for most solutes to keep the IMM and the mitochondrial matrix (MM) 
as separate compartments. It also serves as the site of action for the electron transport chain 
(ETC) and the energy production in form of ATP.  
The mitochondria was observed as early as in the 1850s, but it took more than a century 
before its genome was discovered in the 1960s (Zick et al., 2009). According to the 
endosymbiosis theory, when the bacterium entered the cell it brought its own genome. During 
evolution most of the protein coding has been transferred to the nucleus, but there is still some 
intact genome left in the mitochondrion which codes for 13 proteins necessary in the 
respiratory complexes and RNAs necessary for the translocation (Taylor and Turnbull, 2005; 
Nunnari and Suomalainen, 2012).  
One of the most important tasks of the mitochondria is the production of ATP which counts 
for 90% of the energy needed in the cells and tissues (Kowald and Kirkwood, 2011a; Marchi 
et al., 2012). The mitochondria also function as a control point for the onset of apoptosis and 
have been shown to play a role in aging and different human disorders (Zick et al., 2009). 
The location of the mitochondria correspond to the energy consumption of the cell where the 
cells with the highest need of energy have the highest number of mitochondria and they tend 






2.1.2 Metabolic functions 
The mitochondria are often referred to as the “powerhouse” of the cell. However, there are 
also other important activities located in different parts of the mitochondria, for example 
apoptosis (discussed below) and signalling (Zhang and Chan, 2007).  
In this section the focus will be on the mitochondrial metabolic pathway leading to ATP 
synthesis, starting with β-oxidation of fatty acids whose product, acetyl coenzyme A (aCoA), 
is a substrate in the tricarboxylic acid (TCA) cycle taking place in MM. Reduced 
nicotinamide adenine dinucleotide (NADH), produced in TCA cycle, drives the electron 
transport chain (ETC) whose resulting proton gradient across the inner membrane is necessary 
for the synthesis of ATP. 
 
Figure 2 Chemical pathway in β-oxidation of fatty acids (Nelson and Cox, 2008) 
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About 50-75% of fatty acid β-oxidation in animals occurs in the mitochondria, which includes 
fatty acids with a chain length shorter than 16 carbon atoms (Becker et al., 2006a). Longer 
acyl chains are first shortened in peroxisomes before transported to mitochondria for complete 
degradation. Even numbered acyl chains with number of C = n will, after complete β-
oxidation, result in n/2 aCoA and (n/2)-1 fully reduced flavin adenine dinucleotide (FADH2) 
and NADH as illustrated in Figure 2. 
ACoA can also be obtained from glycolysis where the primary end product is pyruvate. 
Through the IMM, the pyruvate carrier transports pyruvate into the MM where pyruvate 
dehydrogenase oxidizes pyruvate to aCoA with the help of coenzyme A and (nicotinamide 
adenine dinucleotide) NAD
+
 resulting in CO2 and NADH as by-products.  
To enter the TCA cycle aCoA condensation with oxaloacetate to generate citrate is catalysed 
by citrate synthase, as shown in Figure 3. One water molecule is consumed as the coenzyme 
A (CoA) and one proton is released.  
Via the intermediate cis-aconitate, citrate is transformed to isocitrate by the bidirectional 
aconitase. The next step is also via an intermediate, the unstable oxalosuccinate is formed by 
oxidation catalyzed by isocitrate dehydrogenase with help of NAD
+
 forming NADH followed 
by decarboxylation into α-ketoglutarate with release of CO2. A further oxidation catalyzed by 
α-ketoglutarate dehydrogenase and inclusion of NAD
+
 and CoA results in succinyl CoA and 
release of CO2 and the generation of another NADH. Conversion of succinyl CoA to 
succinate is catalyzed by the bidirectional succinyl-CoA synthetase and the CoA is released 
again. In the same step an inorganic phosphate is condensed with guanosine 5’-diphosphate 
(GDP) forming guanosine 5’-triphosphate (GTP) which can return to GDP by giving one 
phosphate to adenosine diphosphate (ADP) resulting in formation of one ATP. 
Succinate dehydrogenase catalyzes the oxidation of succinate to fumarate and one FADH2 is 
formed from flavin adenine dinucleotide (FAD). Fumarate hydratase then consumes one 
water molecule in order to hydrate fumarate to malate. Further oxidation by malate 
dehydrogenase results in oxaloacetate with additional formation of NADH from NAD
+
 and 
release of a proton. The cycle can then start over again with inclusion of a new aCoA. 
To summarize, the TCA cycle produce three NADH, two protons, one FADH2 and one ATP 





Figure 3 Tricarboxylic acid cycle (Becker et al., 2006b) 
 
The ETC, also called respiratory chain, is a set of complexes gathered in the IMM.  The 
bottom line of the electron transport is the transport of electrons from coenzymes like NADH 
to molecular oxygen, and the function of the complexes is to link this transfer of electrons 
with the pumping of protons from MM to IMS (Weiss et al., 1991). However, it is not as 
straight forward as indicated in Figure 4. 
 




Complex I, also called NADH-coenzyme Q (CoQ) oxidoreductase, transfer two electrons 
from NADH to CoQ resulting in binding of two protons. Each pair of electrons that passes the 
complex results in pumping of four protons across the membrane directly from MM. 
Complex II, also called succinate-CoQ oxidoreductase, transfers two electrons to CoQ from 
FADH2. No proton pumping is coupled with this electron transfer.  
Complex III, also called CoQ-cytochrome c (cyt c) oxidoreductase, transfers the electrons 
from CoQ to cyt c. Each pair of electrons that passes the complex results in pumping of four 
protons across the membrane, two which comes from CoQ and two directly from MM. 
Complex IV, also called cyt c oxidase, transfers the electrons from cyt c to oxygen. Each pair 
of electrons entering the complex results in removal of four protons from MM. Two of those 
protons are used to make a water molecule together with one half of an O2 molecule. The two 
remaining protons are just pumped across the membrane. 
The ATP synthase, also called complex V in ETC, is located in the IMM where it uses the 
protons pumped out into the IMS by the ETC to drive the condensation of ADP to ATP, as 
illustrated in Figure 5. For each proton entering the MM though the IMM traversing part of 
the protein, one ADP and inorganic phosphate group is docked into binding sites, one ADP 
and inorganic phosphate group is condensed to ATP in another binding site and one ATP is 
released from a third binding site. This means that three protons are necessary to pass through 
the protein in order to complete one condensation process.  
 
Figure 5 ATP production in inner mitochondrial membrane and coupling with electron 




Apoptosis is programmed killing of cells in a way that is as gentle as possible to the 
surrounding cells (Indran et al., 2011) and it is essential both in organ development and in life 
as general (Desagher and Martinou, 2000). There are 2 main initial routes of apoptosis, as 
shown in Figure 6, one being activation due to cell death signal, left side, and the other being 
activation by removal of survival factors, right side.  There have been discovered cross talking 
between the routs (Wang and Youle, 2009), but it is the latter one will be in focus here.  
 
Figure 6 Schematic steps in apoptosis (Becker et al., 2006c) 
 
Survival, or trophic, factors keeps the cells alive. This is maintained by inhibiting activation 
of pro-apoptotic proteins, for example Bcl-2-associated X protein (Bax). In the absence of this 
factors, pro-apoptotic proteins will be activated and then accumulate in the OMM leading to 
release of IMS proteins like cyt c (Wang and Youle, 2009). However, there is always a 
10 
 
balance in the OMM between anti-apoptotic, for example B-cell lymphoma-2 (Bcl-2), and 
pro-apoptotic factors. The main function of anti-apoptotic factors has been shown to be 
preventing of cyt c release (Desagher and Martinou, 2000), but when the balance shifts 
towards pro-apoptotic factors the activation of apoptosis will start.  
The cytosolic cyt c binds to an adaptor protein, apoptosis protease-activating factor 1 (Apaf-
1), with help of ATP, making apoptosomes, and this complex will then activate the first 
caspase in the cascade; one caspase activates the next ending in activation of apoptotic 
morphological changes (Schug and Gottlieb, 2009). Cyt c release have been stated as a “point 
of no return” in apoptosis (Gogvadze et al., 2009), however, if the caspase activity is blocked 
it has been shown that the on-going process towards apoptosis will stop, which indicates how 
finely tuned and tightly controlled this process is (Wang and Youle, 2009). 
 
 
2.1.4 Fusion-fission cycle 
Fusion and fission are very common in the body and include exo- and endocytosis, 
fertilization and cell division. Mitochondrial fusion and fission are constant on-going 
processes (Westermann, 2010), as illustrated in Figure 7. However, the exact mechanism and 
the function of the alternating fusion and fission of mitochondria are still not totally clear. The 
main problem seems to be how the fusion of the outer and inner membranes is coordinated 
relative to each other.  
Experiments have shown that mitofusins 1 and 2 (Mfn1 and Mfn2) in the OMM and optic 
atrophy protein 1 (OPA1) in the IMM are essential in the mitochondrial fusion process 
(Westermann, 2010; Zungu et al., 2011). Mfn1 tends to facilitate the membrane tethering of 






Figure 7 Overview of mitochondrial fusion-fission cycle (Westermann, 2010) 
 
Since mitochondria are unequally distributed throughout the cell their need for proteins varies 
due to different metabolic activity. Fusion might then solve the problem regarding accurate 
delivery to each organelle (Kowald and Kirkwood, 2011b). It has been shown that fusion 
depend on functional membrane potential and mitochondria with a diminished membrane 
potential will thereby be excluded (Twig et al., 2008), however, it might also play a role in 
repair of slightly damaged mitochondria (Zungu et al., 2011). Pro-apoptotic factors are 
thought to regulate mitofusin function and thereby regulate fusion which leads to the 
assumption that fusion protect against apoptosis. (Zhang and Chan, 2007). 
The cytosolic dynamin-related protein-1 (Drp-1) and fission protein 1 (Fis1) in the OMM are 
shown to be essential in the mitochondrial fission process (Zungu et al., 2011). Drp-1 lack 
docking protein in the membrane and therefor use Fis-1 as an adaptor protein to initiate 
fission, then dislocates back to cytosol after completed fission (Zungu et al., 2011). 
Fission is an important quality control where damaged mitochondria can be removed and the 
functional mitochondria can be distributed in the cell according to the local need of ATP 
(Otera and Mihara, 2012). It has also been observed increased fission rate in cells committed 
to apoptosis (Otera and Mihara, 2012) which might correlate to the fragmentation during 
apoptosis. Fission is also important in cell division regarding correct distribution of 




2.1.5 Role in different diseases 
In the 1990s, evidences that mitochondrial dysfunction can cause diseases started to appear 
(Boddapati et al., 2008) and the number of disorders are continuously increasing (Nunnari and 
Suomalainen, 2012). Since mitochondria are present throughout the body, the impaired 
mitochondrial function can cause defects in any organ (Petruzzella et al., 2012). When 
dysfunctional mitochondria accumulate in the cell it will impair cellular function and might 
lead to several chronic diseases (Twig et al., 2008). These disorders are in basic thought to be 
unrelated, but evidence suggests that reactive oxygen species (ROS) is a common factor in the 
pathophysiology (Pieczenik and Neustadt, 2007). 
Most of the mitochondria in the human embryo come from the egg – the contribution from the 
sperm is almost negligible (Sato and Sato, 2012). As a result of this almost all mutations, and 
thereby diseases, are inherited from the mother.  
Diabetes mellitus (DM) is a metabolic disorder divided in two types. Type 1 is characterized 
by total absence of insulin production as a result of pancreatic β-cell destruction while type 2 
is characterized by insulin resistance and decreased insulin secretion (Correia et al., 2012). It 
has been thought that intracellular hyperglycemia can result in increased production of ROS 
and that the following oxidative stress experienced by the cell can contribute to the 
development of DM (Naudi et al., 2012). Hyperglycemia is also responsible for a relative 
decrease of antioxidants, due to increased glucose conversion, leading to increased sensitivity 
to oxidative stress (Rolo and Palmeira, 2006). There are two ways that can link mitochondria 
to the development of DM, the first being inheritance of mtDNA mutation (Enns, 2003) and 
the second being the fact that mitochondria are the main source of ROS with a majority 
generated from ETC (Rolo and Palmeira, 2006). 
Alzheimer’s disease (AD) is a common form of dementia with progressive increase in 
severity (Correia et al., 2012). Damages due to oxidative stress has been observed in AD 
patients (Enns, 2003; Moreira et al., 2010) and appears to be a key factor in both development 
and progression of the disease (Reddy, 2008). Together with a higher risk of AD in patients 





Parkinson’s disease (PD) is a common neurodegenerative disease characterized by muscle 
rigidity and tremor (Enns, 2003) which  is caused by degeneration of dopaminergic neurons in 
substantia nigra (Reddy, 2008). PD has a complex pathophysiology, but oxidative damage 
and reduced function of ETC, especially complex I, have been reported in PD (Enns, 2003; 
Reddy, 2008; Cali et al., 2011) and mtDNA mutations have been observed as possible and 
partly explanations for ECT dysfunction (Reddy, 2008; Cali et al., 2011). 
Cancer cells, whose natural onset of apoptosis is silenced, have a high rate of cell division 
(Gogvadze et al., 2009). Healthy cells get most of their ATP from ETC in mitochondria while 
cancer cells instead use up-regulated glycolysis as the main energy source (Indran et al., 
2011). There have been shown a proportional relationship between increased rely on 
glycolysis and aggressiveness of tumor cells (Gogvadze et al., 2009). ROS have a dual role 
regarding cancer since oxidative stress can lead to mutations or damages resulting in tumor 
development and the elevated level in cancer cells are vital to cell survival, but in excessive 
amounts it will lead to cell death (Azad et al., 2009). Both physiological alteration, like fewer 
mitochondria per cell, with smaller size and increased membrane potential (Indran et al., 
2011), and down-regulated metabolic activity (Gogvadze et al., 2009) might explain the 




2.1.6 Strategies for mitochondrial targeting 
The goal with targeted therapy is to selectively treat the affected organ and not interfere with 
healthy parts (Torchilin, 2010). This will lead to lower dose needed for the treatment and 
decreased incidents as well as severity of side effects.  
Targeting can be divided into passive and active targeting. The former can be used in 
targeting tumors, for instance, where it takes advantage of the enhanced permeation and 
retention (EPR) effect, which relies on more leaky blood vessels relative to blood vessels in 
healthy tissue (Bitounis et al., 2012). When the cells or even subcellular organelles are to be 
reached, the therapy must be actively and selectively targeted. There are several possibilities 
in active targeting, but only a few are presented here. They focus on the fact that 
mitochondrial dysfunction can cause disorders and have therefor a common goal of inducing 
cell death, a concept introduced about 15 years ago (Weissig, 2011). 
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In cells resistant to chemotherapy the have been observed overexpression of anti-apoptotic 
Bcl-2 (Kang and Reynolds, 2009). Changes in sensitivity to apoptosis result in damaged cells 
and organelles not being removed and might lead to growth of cancer cells. The Bcl-2 would 
then be an appropriate target and down regulation, which would result in OMM 
destabilization and thereby cyt c release, can be achieved both on messenger RNA (mRNA) 
and protein level. A similar destabilization of OMM can be caused by inhibition of 3-
hydroxy-3-methyl-guaryl (HMG) CoA reductase which results in decreased amount of 
cardiolipin produced that can stabilize the membrane (Gogvadze et al., 2009). 
The majority of energy production in tumor cells is due to glycolysis, even though the 
mitochondria have a much higher output. In the glycolytic pathway one glucose and two ATP 
are consumed resulting in two pyruvate and four ATP. The net energy output is then two ATP 
in contrast to a total of 47 ATP after one complete cycle starting from production of one 
aCoA and ending with complex V. If glycolysis in or glucose transport into the tumor cells 
are depressed the ATP level will decrease. This will lead to permeabilization of OMM and 
thereby release of pro-apoptotic factors localized in IMS, resulting in massive cell death 
(Gogvadze et al., 2009).  
A direct change in mitochondrial activity might be another way in which cell death can be 
induced. Inhibition of ETC will cause increased amount of ROS (Chen et al., 2007). In low 
levels, ROS act as signalling molecules which is important in cell survival, but when the 
levels of ROS  increases it will cause cell death (Azad et al., 2009). 
The approaches presented so far have been on targeting specific mitochondrial functions. Yet 
another way is achieving targeting based on the affinity.  
Mitochondriotropic molecules are substances that, due to the membrane potential, will 
specifically accumulate in the mitochondria. One such example is triphenylphosphonium 
(TPP). By linking the TPP to a fatty acid it is possible to incorporate it in lipid membranes 
and thereby use it as a targeting moiety on liposome surface. Experiments have shown that 
TPP facilitates subcellular delivery and that incorporated drug shows increased induction of 






2.2.1 Liposomes as carrier systems 
Liposomes are spherical lipid vesicles normally prepared from phospholipids which makes 
them biocompatible and biodegradable and thereby nontoxic (Lasic, 1998). They are of 
different size and with different number of lipid bilayers, or lamellas, and can be defined as:  
Multilamellar vesicles (MLV) are generally referred to as larger than 100 nm and can 
range up to several µm.  
Unilamellar vesicle can be divided into:  
- Small unilamellar vesicles (SUV) with a general size bellow 100 nm, 
- Large unilamellar vesicles (LUV) with a general size lager than 100 nm, and 
- Giant unilamellar vesicles (GUV) with a general size larger than 1 µm (Martin 
et al., 2006).  
A great variety of components can use liposomes as carrier or protection since hydrophilic 
compounds can be encapsulated in the aqueous core and lipophilic and amphiphilic 
compounds can be incorporated in or associated with the lipid bilayer (Torchilin, 2005) as 
illustrated in Figure 8. This provides liposomes with a wide potential to be used in 
therapeutic, and cosmetic, applications.  
 




One major drawback in liposomal pharmacotherapy is their fast clearance from blood through 
the mononuclear phagocyte system (MPS). To increase the circulation time, different 
hydrophilic polymers have been attached to the surface of the liposomes, where polyethylene 
glycol (PEG) is the most studied (Torchilin, 2005). It has also been reported that high-density 
lipoprotein (HDL) and low-density lipoprotein (LDL) reduce the liposomal stability as a 
result of lipid transfer, which have been solved by adding cholesterol to the liposomes 
(Bitounis et al., 2012).  
However, major advantage with liposomal delivery over free drug delivery is the ability to 
target the pharmacological treatment to specific sites and thereby reducing the occurrence and 
severity of side effects (Lasic, 1998).  
 
 
2.2.2 Lipids  
Lipids can be defined both due to their biological function and their chemistry. The lipids in 
focus here are categorized as important for the structure of membranes and are chemically 
called glycerophospholipids (GPL). Glycero- refers to the glycerol backbone and the –
phospho- refers to the phosphate binding the polar head group (denoted R-group) to the 
glycerol, as shown in Figure 9. In biological membranes the acyl chain connected to C1 is 
usually saturated with 16-18 carbon atoms while the acyl chain at C2 usually is unsaturated 
and has 18-20 carbon atoms.   
 
Figure 9 General structure of glycerophospholipids 
 
Different membranes have different lipid composition due to their biological activity and the 
surrounding temperature. There is variation within the same membrane as the inner and outer 
layer in the lipid bilayer serve different purposes and also inside the leaflets as lipids tend to 
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aggregate into lipid rafts or lateral lipid domains (Welti and Glaser, 1994).  Even though the 
GPLs serve as structural elements they play, in addition, important roles as second 
messengers and binding sites for proteins. 
 
Cardiolipin (CL) is an anionic GPL with four acyl chains, due to linkage of two phosphate 
groups as shown in Figure 10, in contrast to the normal two. It is, in eukaryotes, found only in 
or associated with mitochondrial inner membrane and is important in energy metabolism and 
electron transport (Hoch, 1992; Scherer and Schmitz, 2011) and is binding site for Ca
2+
 (Nie 
et al., 2010). CL is protective in apoptosis as decreased CL level leads to increased 
cytochrome c release (McMillin and Dowhan, 2002). In addition it serves as site for contact 
of inner and outer mitochondrial membrane (Houtkooper and Vaz, 2008) and might then play 
an important role in mitochondrial fusion-fission cycle. 
 
Figure 10 Molecular structure of R-group in cardiolipin 
 
Phosphatidylcholine (PC) (structure shown in Figure 11), also called lecithin, is a zwitter 
ionic GPL and the most common in mammalian membranes (Niebergall and Vance, 2012). It 
is mainly found in the outer part of the lipid bilayer (Marconescu and Thorpe, 2008) and is 
more frequently localized outside the lipid rafts rather than in the rafts (Ehehalt et al., 2010). 
The function of several pro-inflammatory receptors tend to depend on lipid rafts and might 
thereby be affected by PC concentration (Ehehalt et al., 2010). 
 




Phosphatidylethanolamine (PE) (structure shown in Figure 12) is a zwitter ionic GPL and the 
second most common in mammalian membranes (Niebergall and Vance, 2012). It is mainly 
found in the inner part of the lipid bilayer, but is enriched on the surface blebs of apoptotic 
cells (Marconescu and Thorpe, 2008). 
 
Figure 12 Molecular structure of R-group in phosphatidylethanolamine 
 
Phosphatidylglycerol (PG) (structure shown in Figure 13) is an anionic GPL. In addition to 
serving as a messenger itself, PG is a substrate in the biosynthesis of CL and is, therefore, 
indirectly of high importance in mitochondrial function (Nie et al., 2010). 
 
Figure 13 Molecular structure of R-group in phosphatidylglycerol 
 
Phosphatidylinositol (PI) is an anionic GPL with a large head group (see Figure 14) and it is 
mainly found in the inner part of the lipid bilayer (Marconescu and Thorpe, 2008). As a result 
of this large head group it might contribute to a looser packaging and thereby result in a more 
fluidic membrane (Peng et al., 2012). PI might also have some kind of “stealth” properties as 
inclusion in vesicles has showed increased circulation time (Roerdink et al., 1983; Wassef and 
Alving, 1993). Phosphorylation might occur at position 3, 4 and/or 5 and this groups plays 
important roles to several proteins’ activity and in generating second messengers (Farooqui et 
al., 2000).  
 
Figure 14 Molecular structure of R-group in phosphatidylinositol 
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2.3 Fluorescent dyes 
Octadecyl rhodamine B chloride (R18) is a cationic fluorophore whose structure is shown in 
Figure 15. At concentration around 9 mol% relative to total lipid, R18 shows the highest 
effect of quenching and lower concentrations tend to be proportional with the degree of 
quenching (Hoekstra et al., 1984). Due to this self-quenching, R18 is a good choice of 
fluorescent dye for use in membrane fusion testing (Biotium, 2006) since fusion of labelled 
and non-labelled membranes decreases the density of R18 and thereby decreasing the effect of 
self-quenching, resulting in increased fluorescent intensity. Excitation wavelength for R18 
used in this work was 560 nm and emission wavelength 590 nm. 
 
Figure 15 Molecular structure of R18 (Biotium, 2006) 
 
Rhodamine 123 (R123) is also a cationic fluorophore whose structure is shown in Figure 16. 
It shows selective localization in mitochondria which is thought to be related to the opposing 
charges of the negative mitochondria and positive dye (Zhang and Chan, 2007). The negative 
charge of the mitochondria is a direct result of the membrane potential and changes will affect 
the fluorescent intensity of R123 (Huang et al., 2007). During exposure to cells, it tends to 
have a time dependent toxicity. After 10 minutes incubation no toxic effects are observed 
(Chen, 1989), while longer incubation cause inhibition of mitochondrial function (O'Connor 
et al., 1988; Hu et al., 2000). Excitation wavelength for R123 used in this work was 503 nm 





Figure 16 Molecular structure of R123 (AnaSpec, 2009) 
 
Calcein is a hydrophilic fluorophore whose structure is shown in Figure 17. It has been shown 
not to interact with bilayers and not affected by pH around physiologic value, and is therefore 
suitable for studying liposome stability (Grit and Crommelin, 1992). It is used in 
encapsulation as a model for hydrophilic drugs with intermediate molecular weight (Bahia et 
al., 2010), however, calcein might affect the kinetics of phospholipid hydrolysis (Grit and 
Crommelin, 1992). Excitation wavelength for calcein used in this work was 496 nm and 
emission wavelength 524 nm. 
 





3 Aim of the work 
Several diseases are caused by mitochondrial dysfunction. An ability to kill the responsible 
cells or organelles might therefor be used as a cure. 
The liposomes in this work have a composition that mimics that of the outer mitochondrial 
membrane from Guinea-pig liver. The approach was based on their ability to be recognized as 
mitochondria, thus the name mito-liposomes, and be included in the fusion-fission cycle, 
thereby being able to act as drug delivery system targeting mitochondria.  
In closer details the focus was on: 
 Preparing liposomes with different lipid composition to optimize the fusion efficiency 
with mitochondria 
 Trace the stability of the liposomes under normal storage conditions 
 Isolate functional mitochondria from pig liver to test the fusion 
 Preliminary experiments with encapsulation of dye to control uptake by fusion contra 








4 Materials and Methods 
4.1 Materials 
4.1.1 Chemicals 
Adenosine 5’-diphosphate sodium salt (ADP), Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Albumin from bovine serum (BSA), Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ammonium molybdate tetrahydrate, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Calcein, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Chloroform, Carl Roth GmbH, Karlsruhe, Germany 
D-Mannitol, Carl Roth GmbH, Karlsruhe, Germany 
D(+)-Sucrose, Carl Roth GmbH, Karlsruhe, Germany 
Dimethyl sulphoxide (DMSO), Carl Roth GmbH, Karlsruhe, Germany 
Ethanol (EtOH), Carl Roth GmbH, Karlsruhe, Germany 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany 
Fiske-Subbarow-Reducer, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Hydrochloric acid 37%, Carl Roth GmbH, Karlsruhe, Germany 






Lipids: Cardiolipin sodium salt from bovine heart (CL), purity ≥98%, Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany 
L-α-Phosphatidylinositol ammonium salt from Glycine max (soybean) (SPI), purity 
≥97%, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Phosphatidylcholine from egg yolk lecithin (EPC), purity ≥96%, Lipoid GmbH, 
Ludwigshafen, Germany 
Phosphatidylethanolamine from egg yolk lecithin (EPE), purity ≥97%, Lipoid GmbH, 
Ludwigshafen, Germany 
Phosphatidylglycerol from egg yolk lecithin (EPG), purity ≥98%, Lipoid GmbH, 
Ludwigshafen, Germany 
Methanol (MeOH), Carl Roth GmbH, Karlsruhe, Germany 
3-(N-morpholino)-propanesulfonic acid (MOPS), Carl Roth GmbH, Karlsruhe, Germany 
Octadecyl rhodamine B chloride (R18), Biotium, Inc., Hayward, CA, USA 
Potassium chloride, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Potassium hydrioxide,  Merck KGaA, Darmstadt, Germany 
Potassium phosphate dibasic trihydrate, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Potassium phosphate monobasic, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Rhodamine 123 (R123), AnaSpec, Inc., San Jose, CA, USA 
Sepharose CL-4B, GE Healthcare, München, Germany 
Sodium pyruvate, Biochrom AG, Berlin, Germany 
Sulphuric acid, Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Tetrasodium pyrophosphate, Carl Roth GmbH, Karlsruhe, Germany 
Tris-(hydroxymethyl)-aminomethan (Tris), Carl Roth GmbH, Karlsruhe, Germany 
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4.1.3 Working buffers and solutions 
0.1 M EGTA/Tris 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) (1.905 g) 
was dissolved in Millipore water (50 ml) and pH adjusted to 7.4 with 3-(N-
morpholino)-propanesulfonic acid (MOPS). Stored at 4 °C. 
0.1 M Tris/MOPS 
Tris-(hydroxymethyl)-aminomethan (Tris) (6.05 g) was dissolved in Millipore water 
(500 ml) and pH adjusted to 7.4 with Tris. Stored at 4 °C. 
Isolation buffer (IB) 
Sucrose (34.23 g), EGTA/Tris (5 ml 0.1 M) and Tris/MOPS (50 ml 0.1 M) were 
dissolved in Millipore water (total volume 500 ml) and pH adjusted to 7.4 with Tris 
and MOPS. Stored at 4 °C. 
Respiring buffer 
EGTA (0.475 g), potassium phosphate dibasic trihydrate (0.571 g), potassium chloride 
(4.846 g), MOPS (2.903 g) and tetrasodium pyrophosphate (0.223 mg) were dissolved 
in Millipore water (total volume 500 ml) and pH was adjusted to 7.15 with potassium 




Dimethyl sulphoxide (DMSO) (20 ml), sucrose (2.3961 g) and mannitol (3.8262 g) 
were dissolved in Millipore water (total volume 100 ml) and pH was adjusted to 7.5 
with Tris and MOPS. Stored at 4 °C. 
Thawing medium 
Tris (0.1211 g) and sucrose (8.5575 g) were dissolved in Millipore water (total volume 
100 ml) and pH was adjusted to7.5 with hydrochloric acid.  BSA (0.4 g) was added 
prior the actual use. Stored at -80 °C. 
R123 stock solution (5 mM) 
Rhodamine 123 (R123) (3.808 mg) was dissolved in absolute ethanol (2 ml). Stored at 
-80 °C protected from light.  
ADP stock solution (10 mM) 
Adenosine 5’-diphosphate sodium salt (ADP) (4.27 mg) was dissolved in Millipore 
water (1 ml). Stored at -80 °C protected from light. 
CCCP stock solution (4 mM) 
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (8.18 mg) was dissolved in 10 ml 
absolute ethanol. Stored at -80 °C. 
IB-calcein (10 mM) 
Calcein (124.5 mg) was dissolved in IB (20 ml) and pH adjusted to 7.4 with Tris. 






Concentrator: 5301, Eppendorf AG, Hamburg, Germany 
Hand extruder: LiposoFast-Basic, Avestin, Inc., Ottawa, Canada 
Zetasizer: Zetasizer Nano S, Malvern Instruments Ltd, Worcestershire, UK 
UV/visible spectrophotometer: Ultrospec 1000, Parmacia Biotech Biochron, Cambridge, UK 
Copper grid: Quantifoil® S7/2 Cu 400 mesh, holey carbon films, Quantifoil Micro Tools 
GmbH, Jena, Germany 
Cryo-sample container: Model 626-DH, Getan, Inc., Warrendale, Pennsylvania, USA 
Transmission-electron microscope: Leo 912 Ω-mega, LEO Electronenmikroskopie GmbH, 
Oberkochen, Germany 
Transmission-electron microscope: iTEM 5.0 (Build 1054), Olympus Soft Imaging Solutions 
GmbH, Münster, Germany 
Cryo-camera: Cryo-Box 340719, Carl Zeiss MicroImaging GmbH, Jena, Germany 
Camera TEM: Proscan HSC 2, Oxford Instruments, Abingdon, UK 
Photon correlation spectroscopy: Zeta Potential Analysis, Brookhaven, New York, USA 
Fluorometer: Fluorescence Spectrometer LS 55, Perkin Elmer, Waltham, Massachusetts, USA 
Homogenizer: 50 ml glass potter with Teflon pestle, Fisher Scientific, Pittsburgh, 
Pennsylvania, USA 
Centrifuge: 5804 R, Eppendorf AG, Hamburg, Germany 
Centrifuge: Avanti
®
 J-E, Beckman Coulter, Brea, California, USA 




: BS10001, Packard, now: Perkin Elmer, Waltham, Massachusetts, USA 







4.2.1 Liposome preparation  
The liposomes were made by the film method (Torchilin and Weissig, 2003). The lipids and 
the R18 in the amounts as listed in Table 1 were prepared as aliquots and thereby dissolved in 
a mixture of chloroform and methanol (volume ratio 9:1) in a round bottom flask and placed 
on a rotary evaporator to remove the solvent. The water bath was set to 40 °C and the pressure 
was slowly decreased to 260 mBar until a visible lipid film was formed on the bottom of the 
flask. After 10 minutes at 260 mBar the pressure was further decreased to 0 mBar and let to 
stand for 1 hour.  
R18 mito-lipo 1 have the same lipid composition as OMM (Daum, 1985). 
 
Table 1 Lipid composition of the different R18 mito-lipos 
Preparation 
name 
Composition [molar ratio] 
R18 PC PE PI PG CL 
R18 mito-lipo 1 7.50 51.83 24.44 11.93 2.84 1.47 
R18 mito-lipo 2
- 
3.30 - 24.44 11.93 2.84 1.47 
R18 mito-lipo 3
- 
5.52 51.83 - 11.93 2.84 1.47 
R18 mito-lipo 4
- 
6.53 51.83 24.44 - 2.84 1.47 
R18 mito-lipo 5
- 
7.27 51.83 24.44 11.93 - 1.47 
R18 mito-lipo 6
- 
7.38 51.83 24.44 11.93 2.84 - 
R18 mito-lipo 2
+ 
11.70 103.66 24.44 11.93 2.84 1.47 
R18 mito-lipo 3
+ 
9.48 51.83 48.88 11.93 2.84 1.47 
R18 mito-lipo 4
+ 
8.47 51.83 24.44 23.86 2.84 1.47 
R18 mito-lipo 5
+ 
7.73 51.83 24.44 11.93 5.68 1.47 
R18 mito-lipo 6
+ 
7.62 51.83 24.44 11.93 2.84 2.94 
 
The rehydration of the films was done by adding 4 glass balls (Φ ≈ 2 mm) together with a 
specific volume of IB according to a lipid concentration of approximately 5 mM. The flask 
was placed at rotary evaporator for 20 minutes. If there were visible aggregates the flask was 
placed in sonication bath for a few seconds. After removal of the glass beads, the suspension 
was extruded through a 200 nm polycarbonate membrane 21 times, followed by extrusion 
through a 100 nm polycarbonate membrane 21 times and finally through a 50 nm 
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polycarbonate membrane 31 times. The liposomes were stored at 4 °C protected from light till 
further experiments.  
Samples were evaluated for total phosphorous content by Bartlett assay (Bartlett, 1959) and 
cryo-transmission-electron microscopy studies in addition to determination of particle size, 
fluorescent intensity and zeta potential. 
To determine the encapsulation efficiency for calcein, the lipid films was made in the same 
way as described above without inclusion of R18. The rehydration buffer used was IB-
calcein. A step with 3 times freeze-thaw cycles was added to increase the encapsulation 
efficiency, in which the liposomal suspension was frozen in liquid nitrogen, thawed in 25 °C 
water bath for 5 minutes and thoroughly mixed. The suspension was then extruded only 
through a 200 nm polycarbonate membrane 21 times.  
 
 
4.2.2 Encapsulation efficiency 
After extrusion, the calcein containing liposomes was separated from un-entrapped calcein on 
a Spharose CL-4B/IB column. Liposome fractions were evaluated by Bartlett assay (Bartlett, 
1959).  
To determine the encapsulation efficiency, the fluorescence intensity of 0% and 100% 
samples were used as standards. For the 0% value 10% (w/w) Triton (100 μl) was diluted with 
IB (total weight of 10 g). For the 100% value Triton (100 μl 10% (w/w)) and non-separated 
sample (100 μl) were diluted with IB (total weight 10 g). The further dilutions of the samples 
were prepared by diluting 100% sample until the fluorescent intensity was approximately 
800-900.  
For the encapsulation determination, the liposome fraction, after separating sample (100 μl), 
was diluted with IB (total weight 10 g) including Triton (100 μl 10% (w/w)). The same 
dilutions as for 0% and 100% were prepared and the fluorescent intensities used to calculate 











Where Fsample represents the fluorescence intensity of the liposome fraction, F0% represents the 
fluorescence intensity of the 0% standard and F100% represents the fluorescence intensity of 
the 100% standard. 
 
 
4.2.3 Characterization of liposomes 
4.2.3.1 Determination of zeta potential 
Liposome suspension (0.5 ml 5 mM) was diluted in IB (0.5 ml) and transferred to a 
conductive cuvette. The measurements were performed at room temperature. The average of 3 
runs was calculated, each consisting 15 zeta runs. 
The refractive index of the IB was 1.340 and the viscosity was 1.0939 cP (Zhou, 2012). The 
dielectric constant was kept at 78.5. 
 
 
4.2.3.2 Total phosphorous content – Bartlett assay (Bartlett, 1959; Zhou, 2012) 
A potassium phosphate monobasic calibration curve was made with concentration ranging 
from 50 to 350 nmol. Three tubes without any phosphor were used as blanks. Sulphuric acid 
(0.5 ml 10 N) was added to each tube before incubation at 160 °C.  After 3 h hydrogen 
peroxide solution (200 µl 31.2% (w/w)) was added and the incubation continued for another 
1.5 h. Ammonium molybdate solution (4.5 ml 0.22% (w/V)) and Fiske-Subbarow-Reduces 
solution (200 µl 14.8% (w/V)) were added to each tube. The solutions was then mixed using 
vortex mixer before further incubation at 95 °C for 10 minutes. After cooled down to room 





4.2.3.3 Cryo-transmission-electron microscopy (Zhou, 2012) 
Liposome suspension (3 µl 5 mM) was applied to a copper grid and excessive fluid was 
removed with filter paper prior to immediately freezing using liquid ethane. The grid was then 
fixed in a cryo-sample container and inserted in the transmission-electron microscope which 
operated with an acceleration voltage of 120 kV. The pictures were taken with a 
corresponding camera with magnifications ranging from 6300 times to 12500 times. 
 
 
4.2.3.4 Stability testing 
Control experiments were performed to evaluate the stability of the liposome suspensions 
upon storage in 4 °C. The control experiments were done after preparation and after 1 week, 2 
weeks, 3 weeks, 4 weeks, 2 months, 3 months and 4 months.  
Photon correlation spectroscopy (PCS) was used to measure the effective, or hydrodynamic, 
diameter in order to detect possible liposome fusion. The measurements were performed at 
room temperature. Liposome suspension (30 µl 5 mM) was added to sterile filtrated IB (1000 
µl). The count rate was kept between 50 and 60 kcps and the polydispersity was kept bellow 
0.1. Each run lasted 10 minutes and consisted of 5 sub runs. 
A fluorescence spectrometer was used to measure the fluorescence intensity in order to detect 
possible leakage of R18 from the liposomes into the IB. Liposome suspension (5 µl 5 mM) 
was added to sterile filtrated IB (2500 µl). The measurements were performed at room 






4.2.4 Isolation of mitochondria (Frezza et al., 2007; Zhou, 2012)  
Fresh pig liver was brought in ice bath from the slaughterhouse and was kept in ice during all 
preparatory steps. The IB and all centrifugation tubes containing tissue homogenate between 
the centrifugations were also kept in ice bath. During all centrifugations the temperature was 
kept at 4 °C. 
The liver was washed in IB and minced while continuously being hydrated with IB. The 
minced liver was immersed in IB and centrifuged to remove blood. After starting the 
centrifuge, rotation was manually stopped when the speed reached 500 g. The supernatant 
containing the blood was discarded and the process was repeated 2-3 more times until the 
supernatant appeared almost colourless. Connective tissue was removed using forceps before 
diluting with IB in a ratio 4:1 (IB : minced tissue, w/w) for further homogenization in a 50 ml 
precooled glass potter with Teflon pestle. The glass potter was kept on ice and raised/lowered 
3-4 times with a pestle speed of 1600 rpm, as demonstrated in Figure 18. The homogenate 
was centrifuged at 600 g for 10 minutes to precipitate cellular fragments and organelles larger 
than the mitochondria. The supernatant was collected and centrifuged at 7000 g for 10 
minutes to precipitate the mitochondria. The supernatant was discarded, and the pellet re-
suspended in IB. The process was repeated 2 more times. After the last centrifugation, the 
pellet was kept in a concentrated from to preserve the quality of the mitochondria. The 




Figure 18 Illustration photo of homogenization of tissue  
(Photo: Else Mari Ødegaard-Jensen) 
 
 
4.2.5 Freezing and thawing (Zhou, 2012) 
Both tissue and isolated mitochondria were kept frozen in liquid nitrogen and stored at -80 °C 
if not used immediately. The mitochondria did not require any pre-handling, but the tissue 
was first washed in storage medium. 
In order to use the frozen tissue, the thawing medium was first pre-warmed to 45 °C (tissue : 
thawing medium in ration 1:4) and added directly to the frozen tissue. The tissue was agitated 
or stirred in the thawing medium in order to fasten the thawing process. After complete 
thawing of the tissue, it was kept on ice during the isolation as described earlier.  
The frozen isolated mitochondria were thawed by holding the tube manually or through use of 




4.2.6 Viability testing 
4.2.6.1 Protein concentration assay (Bio-Rad) 
The measurements were done at room temperature and on a microplate. 
For standard curve 3-5 dilutions of BSA were prepared in IB with concentration ranging 
between 0.2-1.5 mg/ml. The mitochondria sample was diluted to desired concentrations. BSA 
standard dilutions (5 μl) and sample dilutions (5 μl) were transferred to microplate. Reagent A 
(25 μl) and Reagent B (200 μl) were added into each well. After gentle agitation, the plate was 
left for 15 minutes protected from light at room temperature for reaction to take place. The 
absorbance was detected at 750 nm using SpectraCount. The protein concentration detected in 
standard samples equals the concentration of mitochondria. 
 
 
4.2.6.2 Dye-time course (Huang et al., 2007; Zhou, 2012) 
The measurements were done at 37 °C (physiological temperature).  
R123 (2.5 µl 35 µM) and sodium pyruvate (250 µl 100 mM) were added to a cuvette 
containing magnetic stirrer and respiring buffer (2247.5 µl). After a few minutes, allowing the 
fluorescence intensity to stabilize, isolated mitochondria (25 µl 100 mg/ml; 1 mg/total ml) 
was added and a drop in fluorescent intensity observed due to self-quenching resulting from 
attractions between positive dye (see Figure 16) and negative mitochondria. After the 
fluorescence intensity was stabilized, ADP (25 µl 10 mM) was added and an increase in 
fluorescent intensity observed due to changed membrane potential resulting from 
condensation of ADP and inorganic phosphate into ATP. If the mitochondria were able to 
synthesize ATP, a drop in fluorescent intensity was observed when all the ADP was used. 
After the fluorescence intensity was stabilized, CCCP (2.5 µl 4 mM) was added as a control 





4.2.7 Fusion experiment (Zhou, 2012) 
To determine the encapsulation efficiency, the fluorescence intensity of 0% and 100% 
samples were used as standards. Both the 0% and the 100% was incubated in a thermomixer 
controlled at 37 °C and with a speed of agitation of 700 rpm for 5 minutes before the 
fluorescent intensity was measured. For the 0% value R18 mito-lipo suspension (10 µl 1mM) 
was added to IB (1990 µl). For the 100% value R18 mito-lipo suspension (10 µl 1mM) and 
Triton (100 µl 10% (w/w)) was added to IB (1890 µl).  
To determine the fusion efficiency R18 mito-lipo suspension (10 µl 1mM) and isolated 
mitochondria (20 µl 100 mg/ml; 1 mg/total ml) were added to IB (1970 µl) and incubated at 
37 °C in a thermomixer with a speed of agitation of 700 rpm for 45 minutes before measuring 
the fluorescent intensity. The fluorescent intensities observed were used to calculate the 








Where Ffusion represents the fluorescence intensity of the fused mito-lipo/mitochondria 
suspension, F0% represents the fluorescence intensity of the 0% standard and F100% represents 





5 Results and discussion 
5.1 Liposome characterization 
The control of particles size in drug delivery is important in order to avoid removal by MPS 
(Brandl, 2001). In addition, sedimentation of particles related to gravity will decrease with 
decreasing size of particles. The liposome suspensions were prepared having a mean size 
around 100 nm and the polydispersity was used as a measure of vesicle size distribution. As 
shown in Table 2, the sizes of liposomes were close to 100 nm and the polydispersities were 
below 0.1, which indicates a narrow size distribution. The exception was R18 mito-lipo 4
-
, 
however, similar results were reported previously (Zhou, 2012). 
 
Table 2 Physical properties of R18 mito-lipos 
 
Effective diameter 
(n = 5) 
Polydispersity 
(n = 5) 
Zeta potential 
(n = 3) 
Size [nm] SD [nm] p.i. SD ζ [mV] SD [mV] 
R18 mito-lipo 1 101.0 1.5 0.056 0.004 -35.8 15.4 
R18 mito-lipo 2
- 
109.4 0.4 0.064 0.010 -43.6 14.6 
R18 mito-lipo 3
- 
101.4 0.4 0.045 0.012 -50.1 14.5 
R18 mito-lipo 4
- 
125.0 0.9 0.173 0.008 -5.5 4.0 
R18 mito-lipo 5
- 
102.2 0.6 0.066 0.017 -46.0 11.7 
R18 mito-lipo 6
- 
106.3 0.7 0.055 0.006 -42.1 11.0 
R18 mito-lipo 2
+ 
99.5 0.4 0.069 0.012 -25.0 14.5 
R18 mito-lipo 3
+ 
99.5 0.6 0.076 0.014 -31.9 14.3 
R18 mito-lipo 4
+ 
97.6 1.7 0.045 0.012 -42.7 17.5 
R18 mito-lipo 5
+ 
93.8 0.6 0.037 0.012 -39.6 15.9 
R18 mito-lipo 6
+ 
100.8 0.8 0.053 0.008 -39.7 15.7 
 
Zeta potential can be used as a measure for the stability of liposome suspension; an increase 
in the absolute value of zeta potential decreases the probability of particle agglomeration 
(Zanatta et al., 2010). Zeta potential has also been linked to opsonization as it is known that a 
zeta potential value close to neutral makes the particle less prone to opsonization and thereby 
results in prolonged circulation time of particle (Kaasalainen et al., 2012).  
Zeta potential has been shown to affect the membrane interactions between cells and non-
specific nanoparticles where positive charged shows enhanced uptake due to the opposite 





would be expected to have the highest fusion efficiency since it had the least negative charge 
(Table 2). 
The actual lipid concentration was measured in order to assure an accurate and comparable 
volume of liposome suspension in the fusion experiments. For the R18 mito-lipos, the results 
are listed in Table 3 and the actual concentration were found to be close to the theoretical 
values.  
 








































Bartlett assay used in determination of phospholipid is determining the total amount of 
phosphor in the sample and it is limited in determination of the relative amount of the 
different lipids present in the liposomal formulation. This is a result of the process of turning 
lipid phosphate groups to free phosphate (Bartlett, 1959; Mrsny et al., 1986). During the 
preparation of liposomes, problems regarding aggregation with some of the liposome 
suspensions led to need for additional sonication in order to obtain homogenous suspensions. 
Due to the colour of the aggregates, it appeared that it was mostly due to un-dissolved R18. 
When liposomes were prepared without any fluorescent dye (data not shown) there were no 
visible aggregates. However, this does not exclude the possibility that the lipids are unevenly 
distributed throughout the liposome membranes and between the liposomes in the 
suspensions. An uneven distribution might cause problems or variability during fusion 
experiments. Still, there is no straightforward way to confirm a homogenous lipid distribution 
and it must therefore be assumed that lipid distribution was even. 
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Micrographs of the liposome suspensions were taken in order to evaluate the shape of the 
liposomes. We wanted to follow possible morphological alterations as a result of different 
lipid compositions of liposomes and the alterations in membrane structure which was 
expected to affect membrane fusion (Roy et al., 2010). Comparison of liposomes with 
different lipid concentration were made, with particular emphasis on the absence of specific 
lipids (Figure 19) relative to double amount of the same lipid (Figure 20) related to effect of 
fusion. 
All preparations showed irregular liposomes with large cavities, but R18 mito-lipo 1 was 
thought to contain the most spherical particles. There were also particles of very small sizes 
that might result from the use of 50 nm membrane during extrusion. 
For liposomes containing doubled amounts of PC (Figure 20b), PG (Figure 20e) and CL 
(Figure 20f) high numbers of disc-like liposomes were observed. For PG liposomes, in 
addition, a more regular shape was seen than when PG was absent (Figure 19e), possibly due 
to a stabilizing effect of hydrogen bonds, and for CL liposomes, a more uniform size than 
when CL was absent (Figure 19f). On the other hand, when PC was absent from the 
preparation it tend to contain more spherical particles (Figure 19b). 
Double amount of PI present in liposomes (Figure 20d) appears to have smaller cavities and 
more regular shape than when PI was absent (Figure 19d). This might be related to the large 
head group of PI as it can cause steric hindrance and thereby reduce the presence of cavities, 
or generation of hydrogen bonding to neighbouring lipids and/or buffer (Peng et al., 2012). 
When the amount of PE was double (Figure 20c) it showed fewer cavities than when PE was 
absent (Figure 19c) but the shape of the particles was more irregular.  
Sterols and proteins are present in biological membranes where they appear to have a 
membrane stabilizing role (Churchward and Coorssen, 2009; Roy et al., 2010). The prepared 
liposomes did not contain such stabilizers which might be one explanation to the folds and 















Figure 19 Cryo-Transmission-Electron micrographs  
of liposomes lacking specific lipids: 
a) R18 mito-lipo 1; b) R18 mito-lipo 2
-
; c) R18 mito-lipo 3
-
;  
d) R18 mito-lipo 4
-
; e) R18 mito-lipo 5
-

















Figure 20 Cryo-Transmission-Electron micrographs  
of liposomes with doubled amount of specific lipids: 
a) R18 mito-lipo 1; b) R18 mito-lipo 2
+
; c) R18 mito-lipo 3
+
;  
d) R18 mito-lipo 4
+
; e) R18 mito-lipo 5
+






5.2 Stability testing of liposomes 
Liposome suspensions are prone to two types of degradation, namely hydrolysis and 
oxidation (Brandl, 2001). As stability of the lipid bilayer is reduced when the lipids are 
degraded (Grit and Crommelin, 1992), change in particle size and fluorescence intensity will 
reflect loss of stability. 
 
 
Figure 21 Changes in mean liposome size over four months period 
  
As Figure 21 indicates, there were some fluctuations in particle size, but from a general view 
the liposomes keep stable. During the storage period no sedimentation was visible, but that 
does not exclude the possibility of uneven distribution throughout the suspension which 
would result in fluctuations as observed. There occurred problems during some of the 
sampling which led to repetition of some measurements. If it was due to the sampling itself or 



































Figure 22 Changes in R18 fluorescence intensity over four months period 
 
Figure 22 shows that the self-quenching effect of R18 was stable throughout the storage 
period. The fluorescent intensity is highly susceptible to changes in both relative dye 
concentration and sample temperature (Trikash et al., 2010). Combined, this suggests that the 
liposomes keep stable in suspension and due to the sensitivity, fluorescent intensity might be 
a more reliable method for evaluating the stability than the size determination. 
The liposomes appeared to retain the incorporated dye under normal storage conditions (4 °C 
and protected from light) for at least four months. However, how much of active ingredient, 
such as drug or protein, will be retained when encapsulated or incorporated cannot be directly 
extrapolated. 
Stability of R18 mito-lipos without specific lipids was not evaluated since previous evaluation 
has shown them to be stable (Zhou, 2012). Due to the low zeta potential of R18 mito-lipo 4
-
 it 






























5.3 Viability testing of mitochondria 
In order to obtain reliable results when studying mitochondrial functions it is important to use 
well-respiring organelles (Frezza et al., 2007). There are several methods for purification of 
mitochondria, but purity and viability have to be estimated (Hornig-Do et al., 2009).  To 
evaluate the viability of the isolated mitochondria, the concentration had to be known and 
protein concentration in the samples (listed in Table 4) was used as a measure for the 
mitochondrial concentration.  
 
Table 4 Protein concentration of isolated mitochondria 
 
Protein concentration  
(n = 3) 
Protein [mg/ml] SD [mg/ml] 
Isolation from fresh tissue 94.11 3.45 
Isolation from frozen tissue 
(thawed and minced with knife) 
52.74 2.62 
Isolation from frozen tissue 
(not thawed and minced with grinder) 
48.82 2.00 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Isolation of mitochondria from fresh tissue was performed together with a well-trained 
personal and the processes were thereby performed at a higher speed. That might be the main 
reason for the high yield. When the isolations were performed from frozen tissue, the process 
was slower which might be the cause both the lower yield and decreased respiration. 
Dye-time course is based on the accumulation of R123 in MM, and thereby self-quenching 
effect, according to mitochondrial membrane potential (Huang et al., 2007). Changes in 
membrane potential leads to altered uptake of R123, resulting in a proportional change in 
fluorescent intensity. 
The mitochondria isolated from fresh tissue (Figure 23) showed decreased viability after 
storage (Figure 24). They also appeared to be non-respiring when isolated from frozen tissue 
(Figure 25 and Figure 26). This may as well be a result of slow experimental handling rather 
than the actual storage since previous (unpublished) experiments have also shown reduced 
viability with increased time used for isolation. It is evident that it is highly recommendable to 




Figure 23 Dye-time course of mitochondria directly after isolation 
 
 
Figure 24 Dye-time course of mitochondria before fusion experiment:  
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Figure 25 Dye-time course of mitochondria isolated from frozen tissue:  
thawed and minced with knife 
 
 
Figure 26 Dye-time course of mitochondria isolated from frozen tissue:  





















Addition of mitochondria 

















Addition of mitochondria 
Addition of ADP 
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5.4 Fusion experiment 
The results from the fusion experiment are summarized in Figure 27, where the fusion 
efficiencies are illustrated relative to the fusion result for R18 mito-lipo 1. R18 mito-lipo 1 
was chosen as a baseline since it had the same composition as the OMM and is, according to 
the hypothesis, recognized as a mitochondrion and included in the fusion-fission cycle.  
 
 
Figure 27 Fusion efficiency of R18 mito-lipos with altered lipid composition relative to 
R18 mito-lipo 1. X-axis show the fusion efficiency of R18 mito-lipo 1, with the standard 
deviation bars at the very left being the standard deviation for R18 mito-lipo 1 
 
When PC was absent the fusion efficiency was increased, and when it was doubled the fusion 
efficiency decreased. As the most common lipid in mammalian membranes, PC would be 
expected to have positive, or at least neutral, effect on the fusion process. However, the 
results showed a clear inhibitory effect. At this point of the project, it is difficult to provide 
deeper insight on why PC is inhibiting rather the improving fusion process.  
On the other hand, when PI was removed the fusion efficiency was decreased, and when it 
was doubled the fusion efficiency increased. This indicates that PI plays an enhancing role in 
the fusion process. The expected increased ability to fuse for R18 mito-lipo 4
-
 due to its zeta 



































very clear. One possible reason why the theory proposed by Kaasalainen and co-workers does 
not correspond to the results presented here might be the complexity of the liposomes 
(Kaasalainen et al., 2012). They were not non-specific in nature but were rather made to 
mimic the composition of the mitochondrial membrane, which can be considered as targeting 
composition. Another possible explanation might be related to the large head group of PI 
(Figure 14). Peng and co-workers showed that inclusion of PI resulted in deeper water 
penetration in the membrane, however, they stated that the lipid had inhibitory effects in 
fusion (Peng et al., 2012). In our case, the opposite was seen.   
The other lipids seemed to have little or no specific effect on the fusion as they were in more 
or less the same region of the scale (Figure 27). However, a slight increase in fusion 
efficiency was observed in liposome preparations containing CL relative to when it was 
removed. Since CL is associated with proteins in ETC and OMM receptors and channels 
(Schug and Gottlieb, 2009), it acts as site for contact of inner and outer mitochondrial 
membrane (Houtkooper and Vaz, 2008), and also plays a role in apoptosis where decreased 
CL level lead to increased cyt c release (McMillin and Dowhan, 2002). It might therefore be 
an important vehicle component for drug delivery to mitochondria. 









, which are the liposomes with the highest and the lowest fusion, respectively, it 
can be concluded that liposomes tend to have a more spherical shape when they are able to 
fuse better. This is a theory supported by previous research as well (Roy et al., 2010). For the 
other samples it appeared that a more uniform size and shape, independent of the actual shape, 




5.5 Encapsulation efficiency 
Based on the results in Figure 27 the R18 mito-lipo 1, R18 mito-lipo 2
-
 and R18 mito-lipo 4
+
 
were selected to be used for further experiments. Calcein was encapsulated in order to 
compare delivery via fusion and direct uptake from buffer to evaluate the efficiency of fusion 
delivery.  
The liposomes with encapsulated calcein were bigger than the R18 mito-lipos. This was to 
assure that calcein would pass the extrusion membrane and that it would stay inside the 
liposomes. As shown in Table 5, the size distribution of the liposomes was narrow.  
 
Table 5 Physical properties of Mito-lipos 
 
Effective diameter  
(n = 5) 
Polydispersity  
(n = 5) 
Size [nm] SD [nm] p.i. SD 
Mito-lipo 1 216.8  3.1 0.069  0.012 
Mito-lipo 2
- 
256.0  4.7 0.042  0.006 
Mito-lipo 4
+ 
266.9 1.3 0.073  0.016 
 
The actual lipid concentrations for the Mito-lipos are listed in Table 6 and it seems that there 
was no lipids present in Mito-lipo 2
-
. However, results in Table 5 indicate the presence of 
particles in the sample, moreover, particles with the expected size. The explanation for this 
discrepancy could be in a fact that the separation of un-encapsulated dye from liposome 
fraction was hard to perform as liposome fraction on the column appeared almost colourless. 
In Mito-lipos 2
-
 there was no coloured band visible on the column other than free calcein. 
This might have resulted in possibly that the actual fraction of liposomes passed through the 
column either before or after the sample was collected. 
 















The amounts of calcein encapsulated in various types of Mito-lipos are listed in Table 7. The 
amount of encapsulated calcein was found to be too small to be followed and provide any 
significant results during fusion experiment, therefor the calcein experiments were stopped at 
this point. 
 
Table 7 Encapsulation efficiency of calcein 
 
Encapsulation efficiency  
(n = 3) 
EE [%] SD [%] 
















It has been stated that methods that base encapsulation on passive diffusion, like the film 
method used here, achieve small amounts of substances encapsulated (Zadi and Gregoriadis, 
2000; Xu et al., 2012). As a result of steric hindrance, molecules with high molecular weight 
might therefore give low encapsulation efficiency (Adrian and Huang, 1979; Brandl, 2001). 
With Lipinski’s “rule of 5” in mind (Lipinski et al., 1997), calcein has a relative high 
molecular weight and with the high number of hydrogen bond acceptors the hydrodynamic 
size of the molecule will increase thereby increasing the steric hindrance.  
Another important fact that might affect the encapsulation process, and possibly also stability, 
is that after lipid film rehydration with IB-calcein, the presence of un-dissolved lipids was 
visible in the samples, floating on the surface. After extrusion, the suspensions were clear, but 
after storage precipitated lipids were observed again. This was not seen with the R18 mito-
lipos, therefor it might be contributed to the effect of calcein. It has been shown that 
liposomes made of phospholipids can hydrolyse in aqueous medium resulting in free fatty 
acids and lyso-phospholipids which will affect the stability of the suspension (Grit and 
Crommelin, 1992). More experiments are needed to clarify this phenomenon, including 






Up to date, there are no published data related the approach used in this project for 
mitochondrial targeting. To take advantage of the alternating fusion-fission cycle of 
mitochondria seems as an interesting way with potential in specific drug delivery and targeted 
distribution.  
The prepared liposomes had a lipid composition similar to the composition of outer 
mitochondrial membrane and variations in the composition were made in order to optimize 
the fusion efficiency.  
Particle size of the different preparations were controlled in the same range, and results of 
four months stability testing suggests that zeta potential did not affect stability of liposomes.  
All liposomal suspensions were able to fuse but their efficiency varied. This indicates that 
some of the lipids play highly positive role in fusion process and other might have limiting 
role. These findings can be used in further optimization of liposomal formulation. We are 










Short term perspectives: 
- Optimize lipid composition relative to fusion efficiency 
- Increase encapsulation efficiency, for example by using a different and/or smaller 
fluorescent dye 
- Compare uptake of hydrophilic substance via fusion and absorption from buffer to 
evaluate the efficiency of the delivery system 
 
Long term perspectives: 
- Evaluate intracellular movement in intact cells 
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